References
- Bibler MR, Peter TF, Hagler DN, Bode RB, Staneck JL, Thamlikitkul V. (1987). Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious Gram-positive infections. Antimicrob Agents Chemother31: 207–212.
- Eggleston M, Ofosu J. (1988). Teicoplanin, a new agent for gram positive bacterial infection. Infect Control Hosp Epidemiol9: 209–211.
- Glupezynski Y, Lagast H, Auwera PV, Thys JP, Crokaert F, Yourassowsky E, Meunier-Carpentier F, Klastersky J, Kains JP, Serruys-Schoutens E. (1986). Clinical evaluation of teicoplanin for therapy of severe infections caused by Gram positive bacteria. Antimicrob Agents Chemother29: 52–57.
- Guzek A, Korzeniewski K, Nitsch-Osuch A, Rybicki Z, Prokop E. (2013). In vitro susceptibility of staphylococci and enterococci to vancomycin and teicoplanin. Adv Exp Med Biol788: 125–132.
- Jovetic S, Zhu Y, Marcone GL, Marinelli F, Tramper J. (2010). β-Lactam and glycopeptide antibiotics: first and last line of defense? Trends in Biotechnol28: 596–604.10.1016/j.tibtech.2010.09.00420970210
- Matthews PC, Chue AL, Wyllie D, Barnett A, Isinkaye T, Jefferies L, Lovering A, Scarborough M. (2014). Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. J Infect68: 43–49.
- Oda K, Kasada T, Yoshikawa M, Tanoue M, Yamashita T, Takeshita Y. (2014). Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients. Ther Drug Monit36(3): 401–405.
- Outman WR, Nightingale CH, Sweeney KR, Quintiliani R. (1990). Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother34: 2114–2117.
- Salimi A, Talaie H, Rezaie Hemami M, Mahdavinejad A, Barari BB, Razi P, Kamalbeik S. (2014). Suggested Teicoplanin as an anti-methicillin resistant staphylococcus aureus agent in infections of severely poisoned intensive care unit patients. Acta Biomed84: 189–195.
- Somma S, Gastaldo L, Corti A. (1984). Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus. Antimicrob Agents Chemother26: 917–923.
- Tobin CM, Lovering AM, Sweeney E, MacGowan AP. (2010). Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J Antimicrob Chemother65: 2155–2157.
- Verbist L, Tijendramaga B, Hendrickx B, Hecken AV, Melle PV, Verbesselt R. (1984). In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother26: 881–886.